Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (17)

Jackson K. Mukonzo (1), Paul Waako (1), Daniel Röshammar (3), Maria Andersson (2), Jan-Olov Svensson (2), Jasper Ogwal-Okeng (1), Lars L Gustafsson (2), Eleni Aklillu (2)

Population Pharmacokinetics of Efavirenz and MDR-1, CY2B6, and CYP3A5 Polymorphisms

R. McGready (1,2,3), J. Tarning (2), N. Lindegardh (2,3), E.A. Ashley (1,2,3), M. Pimanpanarak (1), B. Kamanikom (2), A. Annerberg (2), P. Singhasivanon (2), N.J. White (2,3), F. Nosten (1,2,3)

Population pharmacokinetics of lumefantrine in pregnant women treated with co-artemether for uncomplicated falciparum malaria

S. Goutelle (1,2,3), L. Bourguignon (1,2), P.H. Maire (1,2), M. Van Guilder (3), R.W. Jelliffe (3), J.E. Conte Jr (4,5)

Influence of Rifampin Pharmacokinetic Variability on Antibacterial Effect and Prevention of Resistance in Pulmonary Tuberculosis: a Simulation Study

S. Goutelle (1,2,3), L. Bourguignon (1,2), P.H. Maire (1,2), M. Van Guilder (3), R.W. Jelliffe (3), J. E. Conte Jr (4)

A Population Pharmacokinetic Study of Plasma and Intrapulmonary Concentrations of Rifampin

M. Frank (1), A. Kunz (2), G. Harms (2), C. Kloft (1)

Nevirapine – Population pharmacokinetic model building and simulation for mothers and newborns

Dubois A (1), Duval X (1,2), Peytavin G (2), Taburet AM (3), Goujard C (3), Mentré F (1,2) and the Cophar1-ANRS 102 Trial Group

Population analysis of plasma and intracellular pharmacokinetics of indinavir in HIV-1 infected patients with a stable antiretroviral therapy

Jan-Stefan van der Walt (1), Phumla Sinxadi (1), Karen Cohen (1), Helen McIlleron (1), Gary Maartens (1). Mats O Karlsson (2)

Population pharmacokinetic models for lamivudine and nevirapine to assess drug concentrations obtained during therapeutic drug monitoring

Zhao W (1), Baudouin V (2), Zhang D (1) and Jacqz-Aigrain E (1)

Population Pharmacokinetics of Ganciclovir Following Oral Administration of its Prodrug Valganciclovir in Pediatric Renal Transplant Patients

M. Neely (1), J. van den Anker (2), S. Soldin (2), K. Williams (2), A. Baghdassarian (2), N. Rakhmanina (2)

Population Kinetics and Dynamics of Lopinavir in HIV-Infected Children

García MJ, Santos Buelga D, Cabrera S, Fernandez de Gatta MM, Domínguez-Gil

Population Pharmacokinetics of Efavirenz in HIV-infected patients: Pharmacogenetic analysis

H Kimko, B Murthy, RS Strauss, S Xu, P Bagchi, P Nandy, K Bush, GJ Noel

Relationship Between a PK/PD Parameter and Therapeutic Response of Ceftobiprole in Patients with Complicate Skin and Skin Structure Infection

C. Bazzoli (1), S. Retout (1, 2), E. Rey (3), H. Benech (4), J.M. Tréluyer (3), D. Salmon (5), X. Duval (1, 6, 7), F. Mentré (1, 2) and the COPHAR2- ANRS 111 study group

Population pharmacokinetics of AZT and its active metabolite AZT-TP in HIV patients: joint modelling and design optimisation

C.M.T. Sherwin (1, 2), N.J. Medlicott (2), R. Broadbent (1), D.M. Reith (1).

Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates.

F.T. Musuamba(1), I. Delattre(1), P.F. Laterre(3), J. Cumps(4), F. Jacobs(5), R.K. Verbeeck(2 )and P. Wallemacq(1)

Simultaneous Therapeutic Drug Monitoring Of Amikacin And Beta-Lactams In Intensive Care Unit Patients With Severe Sepsis Or Septic Shock Without Beta-Lactam Serum Concentration Monitoring

Caldes A2 , Colom H1 , Garrido MJ3, Trocóniz I3, Gilvernet S2, Armendariz Y2, Cendrós JM1, Peraire C1 , Grinyó JM2

Population pharmacokinetics of Ganciclovir following Valganciclovir in solid organ transplant recipients infected by cytomegalovirus

Elisabet I Nielsen (1,2), Marie Sandström (1,3), Per Hartvig (2,4), Uwe Ewald (5), Lena E Friberg (1)

Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates: Modelling and Simulation Based on Data from a Prospective Study

C Solas (1), MC Gagnieu (2), I Ravaux (3), MP Drogoul (4), A Lafeuillade (5), S Mokhtari (6), B Lacarelle (1) and N Simon (1).

Population Pharmacokinetics of Atazanavir in HIV-infected Patients